Cargando…

Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)

The EuResist cohort was established in 2006 with the purpose of developing a clinical decision-support tool predicting the most effective antiretroviral therapy (ART) for persons living with HIV (PLWH), based on their clinical and virological data. Further to continuous extensive data collection fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossetti, Barbara, Incardona, Francesca, Di Teodoro, Giulia, Mommo, Chiara, Saladini, Francesco, Kaiser, Rolf, Sönnerborg, Anders, Lengauer, Thomas, Zazzi, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222321/ https://www.ncbi.nlm.nih.gov/pubmed/37235291 http://dx.doi.org/10.3390/tropicalmed8050243

Ejemplares similares

The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
por: Pironti, A, et al.
Publicado: (2010)

Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
por: Weisser, Hendrik, et al.
Publicado: (2010)

Selecting anti-HIV therapies based on a variety of genomic and clinical factors
por: Rosen-Zvi, Michal, et al.
Publicado: (2008)

Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy
por: Altmann, André, et al.
Publicado: (2008)

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy
por: Svärd, Jenny, et al.
Publicado: (2017)

HIV-1 mutational pathways under multidrug therapy
por: Lawyer, Glenn, et al.
Publicado: (2011)

Time on drug analysis based on real life data
por: Schülter, Eugen, et al.
Publicado: (2014)

EuCARE-hospitalised study protocol: a cohort study of patients hospitalised with COVID-19 in the EuCARE project
por: Hedberg, Pontus, et al.
Publicado: (2023)

Using drug exposure for predicting drug resistance – A data-driven genotypic interpretation tool
por: Pironti, Alejandro, et al.
Publicado: (2017)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
por: Kuznetsova, Anna, et al.
Publicado: (2022)

Molecular Epidemiology of HIV-1 in Eastern Europe and Russia
por: van de Klundert, Maarten A. A., et al.
Publicado: (2022)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study
por: Bavaro, Davide F., et al.
Publicado: (2022)

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2023)

Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters
por: Miranda, Mafalda N. S., et al.
Publicado: (2022)

Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2010)

Correction: Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2011)

The Health Gym: synthetic health-related datasets for the development of reinforcement learning algorithms
por: Kuo, Nicholas I-Hsien, et al.
Publicado: (2022)

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors
por: De Luca, Andrea, et al.
Publicado: (2015)

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
por: Picarazzi, Francesca, et al.
Publicado: (2020)

Defining the architecture of KPC-2 Carbapenemase: identifying allosteric networks to fight antibiotics resistance
por: Galdadas, Ioannis, et al.
Publicado: (2018)

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
por: Bartha, István, et al.
Publicado: (2013)

Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro
por: Boccuto, Adele, et al.
Publicado: (2021)

The historical experience and practice of fight against tuberculosis in country which is one of the high drug resistant-tuberculosis (DR-TB) burden countries in European Union (EU)
por: KORABLIOVIENE, J., et al.
Publicado: (2018)

The Fight for Digital Sovereignty: What It Is, and Why It Matters, Especially for the EU
por: Floridi, Luciano
Publicado: (2020)

Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
por: Elvstam, Olof, et al.
Publicado: (2022)

The global burden of HIV-1 drug resistance in the past 20 years
por: Zazzi, Maurizio, et al.
Publicado: (2018)

Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect
por: De Luca, Andrea, et al.
Publicado: (2015)

EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestations
por: Varisco, Benedetta, et al.
Publicado: (2023)

Fighting the COVID-19 Crisis: Debt Monétisation and EU Recovery Bonds
por: Botta, Alberto, et al.
Publicado: (2020)

Phage Products for Fighting Antimicrobial Resistance
por: Huang, Yuanling, et al.
Publicado: (2022)

EuCARDWP4 -Accelerator Networks
por: Zimmermann, F, et al.
Publicado: (2010)

The Multiplex Network of EU Lobby Organizations
por: Zeng, An, et al.
Publicado: (2016)

Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data
por: Pironti, Alejandro, et al.
Publicado: (2017)

The Urgent Need for Novel Antimicrobial Agents and Strategies to Fight Antibiotic Resistance
por: D’Andrea, Marco Maria, et al.
Publicado: (2019)

Fighting SARS with a Hastily Formed Network
por: van Baalen, Peter J., et al.
Publicado: (2009)

Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance
por: Kaiser, Kyra G., et al.
Publicado: (2023)

Pilot testing the EARS-Vet surveillance network for antibiotic resistance in bacterial pathogens from animals in the EU/EEA
por: Lagrange, Justine, et al.
Publicado: (2023)

Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet)
por: Brandenburg, Vincent, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lht2ju8tei1ctqgbv309a6luq4